OncoLens Resources

Mar 08, 2022 | Education

Quality Improvement Program Webinar—NSCLC Biomarker Testing

Feb 04, 2022 | News and Events

The Desmoid Tumor Research Foundation Closes Care Gaps through Virtualized Multidisciplinary Cancer Care Platform

Jan 20, 2022 | News and Events

OncoLens Platform Critical to Meeting the CoC’s Continuous Quality Improvement Requirements

Dec 27, 2021 | Blog

2022 Multidisciplinary Cancer Care Top Five Trends

Dec 17, 2021 | News and Events

OncoLens Celebrates the CoC’s 100th Anniversary

Sep 24, 2021 | Case Studies

Results of a Multi-State, Multi-Institution Implementation of a Multidisciplinary Conference Quality Measurement Tool

Aug 17, 2021 | News and Events

New Markey Initiative Helps Affiliates Deliver Cancer Care Closer to Home

Jun 04, 2021 | Case Studies

Time-Saving Opportunities through Tumor Board and Cancer Registry Integration

Jun 01, 2021 | CME

Molecular Testing in the Community Oncology Setting

Apr 01, 2021 | Education

Lung Cancer Patient with 3 EGFR Mutations

Apr 01, 2021 | Education

Ovarian Cancer Patient with Somatic BRCA1 Reversion Mutation

Apr 01, 2021 | Education

Ovarian and Lung Cancer Patients with BRCA Reversion and Three EGFR Mutations

Mar 01, 2021 | Education

NCCN updates: Stage IB – IIA NSCLC with EGFR Alteration Patients

Mar 01, 2021 | Education

Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result

Mar 01, 2021 | Education

NSCLC Patient and Adjuvant Chemotherapy

Feb 01, 2021 | Education

Patient with Possible Synchronous Early-stage NSCLC and Different DetermaRx Results

Feb 01, 2021 | Education

Patient with NSCLC Who Recurred within a Year

Feb 01, 2021 | Education

Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion

Feb 01, 2021 | Education

Stratification of Early-Stage, Non-squamous NSCLC Patients Likely to Benefit from Early, Post-operative Chemotherapy

Jan 14, 2021 | News and Events

Fast-Growing Oncology Startup OncoLens Secures $7.25 Million Series A Funding

Dec 11, 2020 | Case Studies

Project ECHO® Learning Series

2,000,000+

143,000+

24,000+

Project ECHO® Learning Series

2,000,000+

118,000+

19,000+

OncoLens Resources

Quality Improvement Program Webinar—NSCLC Biomarker Testing

The Desmoid Tumor Research Foundation Closes Care Gaps through Virtualized Multidisciplinary Cancer Care Platform

OncoLens Platform Critical to Meeting the CoC’s Continuous Quality Improvement Requirements

2022 Multidisciplinary Cancer Care Top Five Trends

OncoLens Celebrates the CoC’s 100th Anniversary

Results of a Multi-State, Multi-Institution Implementation of a Multidisciplinary Conference Quality Measurement Tool

New Markey Initiative Helps Affiliates Deliver Cancer Care Closer to Home

Time-Saving Opportunities through Tumor Board and Cancer Registry Integration

Molecular Testing in the Community Oncology Setting

Lung Cancer Patient with 3 EGFR Mutations

Ovarian Cancer Patient with Somatic BRCA1 Reversion Mutation

Ovarian and Lung Cancer Patients with BRCA Reversion and Three EGFR Mutations

NCCN updates: Stage IB – IIA NSCLC with EGFR Alteration Patients

Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result

NSCLC Patient and Adjuvant Chemotherapy

Patient with Possible Synchronous Early-stage NSCLC and Different DetermaRx Results

Patient with NSCLC Who Recurred within a Year

Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion

Stratification of Early-Stage, Non-squamous NSCLC Patients Likely to Benefit from Early, Post-operative Chemotherapy

Fast-Growing Oncology Startup OncoLens Secures $7.25 Million Series A Funding

Best Practices: Building the Future of Multidisciplinary Cancer Care